A new therapeutic approach improves the outcome of patients with (aging-related) COVID-19 Pneumonia
5 views
Skip to first unread message
Ilia Stambler
Mar 7, 2020, 4:26:50 AM3/7/20
to lifeboat-foundati...@googlegroups.com, lifeboat-sab-biotech...@googlegroups.com, lifeboatf...@yahoogroups.com
Dear friends
I would like to bring to your attention the press release by the International Society on Aging and Disease (ISOAD), Shanghai University, Chinese Academy of Medical Sciences & Peking Union Medical College, China:
A groundbreaking new therapeutic approach was developed and tested to improve outcome in patients suffering from novel coronavirus (COVID-19) pneumonia. The new technique involves intravenous transplantation of mesenchymal stem cells (MSCs) into the patients. It was successfully tested in 7 COVID-19 patients, in Beijing YouAn Hospital, Capital Medical University, China. The results are published in the scientific journal Aging and Disease, entitled "Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia" (free on line):
A groundbreaking new therapeutic approach was developed and tested to improve outcome in patients suffering from novel coronavirus (COVID-19) pneumonia. The new technique involves intravenous transplantation of mesenchymal stem cells (MSCs) into the patients. It was successfully tested in 7 COVID-19 patients, in Beijing YouAn Hospital, Capital Medical University, China. The results are published in the scientific journal Aging and Disease, entitled "Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia" (free on line):
http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml
The study was conducted by a team led by Dr. Zhao, with Shanghai University and Chinese Academy of Medical Sciences & Peking Union Medical College, China.
MSCs could cure or significantly improve the functional outcomes of all the seven tested patients without observed adverse effects, contrary to 3 controls. The pulmonary function and symptoms of these seven patients were significantly improved after MSC transplantation. Among them, one severe and two common patients recovered and were discharged in 10 days after the treatment.
The presented evidence suggests that the therapeutic effects are based on the immunomodulatory capacity of mesenchymal stem cells (restoring the balance of the immune system). The coronavirus infection can stimulate a terrible cytokine storm in the lung, disrupting the balance of cytokines (signaling molecules of the immune system) such as IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A and TNFα cytokines, followed by the edema, dysfunction of the air exchange, acute respiratory distress syndrome, acute cardiac injury and the secondary infection, which may lead to death. MSCs could inhibit the over-activation of the immune system and promote endogenous repair by improving the microenvironment, thus they could represent a safe and effective treatment for patients with COVID-19 pneumonia, especially for the patients in critically severe conditions.
Notably, the coronavirus-infected pneumonia is more likely to affect older individuals, especially older males, with comorbidities, resulting in their severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In other words, aging appears to be the main risk factor for bad outcomes. However, the cure essentially depends on the patient's own immune system. When the overactivated immune system kills the virus, it produces a large number of inflammatory factors, leading to the severe cytokine storms. This suggests that the main reason for the organs damage may be the virus-induced cytokine storm. Older subjects may be much easier to be affected due to immunosenescence. The study showed remarkable recovery of the elderly patients thanks to restoring their immune function.
Thus, the study may have a broader significance, even beyond the treatment of the severe coronavirus disease. This study exemplifies that the general therapeutic improvement of the immune system in the elderly can improve outcome and survival, which may have more general relevance for other aging-related communicable diseases. Thus, this study may inspire and pave the way for further promising directions to investigate the connection between aging and disease, and to treat both communicable and non-communicable aging-related diseases.
See the full press release from the International Society on Aging and Disease (ISOAD)
Some press about this research:
In English http://www.china.org.cn/china/2020-03/07/content_75785868.htm
Romanian https://www.libertatea.ro/stiri/interviu-ilia-stambler-tratament-coronavirus-covid-19-2904173
Linkedin
Twitter
The study was conducted by a team led by Dr. Zhao, with Shanghai University and Chinese Academy of Medical Sciences & Peking Union Medical College, China.
MSCs could cure or significantly improve the functional outcomes of all the seven tested patients without observed adverse effects, contrary to 3 controls. The pulmonary function and symptoms of these seven patients were significantly improved after MSC transplantation. Among them, one severe and two common patients recovered and were discharged in 10 days after the treatment.
The presented evidence suggests that the therapeutic effects are based on the immunomodulatory capacity of mesenchymal stem cells (restoring the balance of the immune system). The coronavirus infection can stimulate a terrible cytokine storm in the lung, disrupting the balance of cytokines (signaling molecules of the immune system) such as IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A and TNFα cytokines, followed by the edema, dysfunction of the air exchange, acute respiratory distress syndrome, acute cardiac injury and the secondary infection, which may lead to death. MSCs could inhibit the over-activation of the immune system and promote endogenous repair by improving the microenvironment, thus they could represent a safe and effective treatment for patients with COVID-19 pneumonia, especially for the patients in critically severe conditions.
Notably, the coronavirus-infected pneumonia is more likely to affect older individuals, especially older males, with comorbidities, resulting in their severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In other words, aging appears to be the main risk factor for bad outcomes. However, the cure essentially depends on the patient's own immune system. When the overactivated immune system kills the virus, it produces a large number of inflammatory factors, leading to the severe cytokine storms. This suggests that the main reason for the organs damage may be the virus-induced cytokine storm. Older subjects may be much easier to be affected due to immunosenescence. The study showed remarkable recovery of the elderly patients thanks to restoring their immune function.
Thus, the study may have a broader significance, even beyond the treatment of the severe coronavirus disease. This study exemplifies that the general therapeutic improvement of the immune system in the elderly can improve outcome and survival, which may have more general relevance for other aging-related communicable diseases. Thus, this study may inspire and pave the way for further promising directions to investigate the connection between aging and disease, and to treat both communicable and non-communicable aging-related diseases.
See the full press release from the International Society on Aging and Disease (ISOAD)
And the full free article
In English http://www.china.org.cn/china/2020-03/07/content_75785868.htm
Romanian https://www.libertatea.ro/stiri/interviu-ilia-stambler-tratament-coronavirus-covid-19-2904173
On Facebook
https://www.facebook.com/permalink.php?story_fbid=2853653751349033&id=763771300337299&__tn__=K-R
https://www.linkedin.com/groups/13504310/
https://www.linkedin.com/pulse/new-therapeutic-approach-improves-outcome-patients-ilia-stambler/
Ilia Stambler
Outreach coordinator. International Society on Aging and Disease
Ilia Stambler, PhD
Director of Research and Development. Shmuel Harofe Geriatric Medical Center, Beer Yaakov, Israel, Affiliated to Sackler School of Medicine, Tel-Aviv University http://www.shmuelh.org.il/
Chair. Israeli Longevity Alliance / CSO. Vetek (Seniority) – The Movement for Longevity and Quality of Life (Israel) http://www.longevityisrael.org/
Board member. International Longevity Alliance http://www.longevityalliance.org/ Board member. International Society on Aging and Disease http://www.isoad.org Fellow, Policy Director. Global Healthspan Policy Institute https://healthspanpolicy.org/
Author. Longevity History. A History of Life-Extensionism in the Twentieth Century ; Longevity Promotion: Multidisciplinary Perspectives http://longevityhistory.com
Email: ilia.s...@gmail.com
Tel: 972-3-961-4296 / 0522-283-578
Skype: iliastam
Rishon Lezion. Israel
Re Rose
Mar 25, 2020, 10:52:43 AM3/25/20
to Lifeboat Foundation - Life Extension Board
Thanks for posting this - great resource! --Regina
On Saturday, March 7, 2020 at 4:26:50 AM UTC-5, ilia.stambler wrote:
Dear friends
I would like to bring to your attention the press release by the International Society on Aging and Disease (ISOAD), Shanghai University, Chinese Academy of Medical Sciences & Peking Union Medical College, China:
Reply all
Reply to author
Forward
0 new messages